vs

Side-by-side financial comparison of SELECT MEDICAL HOLDINGS CORP (SEM) and Zebra Technologies (ZBRA). Click either name above to swap in a different company.

Zebra Technologies is the larger business by last-quarter revenue ($1.5B vs $1.4B, roughly 1.1× SELECT MEDICAL HOLDINGS CORP). Zebra Technologies runs the higher net margin — 4.7% vs 1.4%, a 3.3% gap on every dollar of revenue. On growth, Zebra Technologies posted the faster year-over-year revenue change (10.6% vs 6.4%). Zebra Technologies produced more free cash flow last quarter ($327.0M vs $5.2M). Over the past eight quarters, Zebra Technologies's revenue compounded faster (12.0% CAGR vs 2.8%).

Select Medical is a healthcare company based in Pennsylvania. It owns long-term acute care and inpatient rehabilitation hospitals, as well as occupational health and physical therapy clinics. Select Medical is a subsidiary of Select Medical Holdings, which is listed on the New York Stock Exchange.

Zebra Technologies Corporation (ZBR), commonly known as Zebra, is an American multinational technology conglomerate corporation specializing in smart data capture systems. Zebra is headquartered in Lincolnshire, Illinois outside of Chicago with 10,700 employees across 57 countries.

SEM vs ZBRA — Head-to-Head

Bigger by revenue
ZBRA
ZBRA
1.1× larger
ZBRA
$1.5B
$1.4B
SEM
Growing faster (revenue YoY)
ZBRA
ZBRA
+4.2% gap
ZBRA
10.6%
6.4%
SEM
Higher net margin
ZBRA
ZBRA
3.3% more per $
ZBRA
4.7%
1.4%
SEM
More free cash flow
ZBRA
ZBRA
$321.8M more FCF
ZBRA
$327.0M
$5.2M
SEM
Faster 2-yr revenue CAGR
ZBRA
ZBRA
Annualised
ZBRA
12.0%
2.8%
SEM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SEM
SEM
ZBRA
ZBRA
Revenue
$1.4B
$1.5B
Net Profit
$20.2M
$70.0M
Gross Margin
47.3%
Operating Margin
4.6%
9.4%
Net Margin
1.4%
4.7%
Revenue YoY
6.4%
10.6%
Net Profit YoY
225.7%
-57.1%
EPS (diluted)
$0.17
$1.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SEM
SEM
ZBRA
ZBRA
Q4 25
$1.4B
$1.5B
Q3 25
$1.4B
$1.3B
Q2 25
$1.3B
$1.3B
Q1 25
$1.4B
$1.3B
Q4 24
$1.3B
$1.3B
Q3 24
$1.3B
$1.3B
Q2 24
$1.3B
$1.2B
Q1 24
$1.3B
$1.2B
Net Profit
SEM
SEM
ZBRA
ZBRA
Q4 25
$20.2M
$70.0M
Q3 25
$28.8M
$101.0M
Q2 25
$40.6M
$112.0M
Q1 25
$56.7M
$136.0M
Q4 24
$-16.1M
$163.0M
Q3 24
$55.6M
$137.0M
Q2 24
$77.6M
$113.0M
Q1 24
$96.9M
$115.0M
Gross Margin
SEM
SEM
ZBRA
ZBRA
Q4 25
47.3%
Q3 25
48.0%
Q2 25
47.6%
Q1 25
49.3%
Q4 24
48.6%
Q3 24
48.8%
Q2 24
48.4%
Q1 24
47.9%
Operating Margin
SEM
SEM
ZBRA
ZBRA
Q4 25
4.6%
9.4%
Q3 25
5.4%
13.9%
Q2 25
6.5%
14.2%
Q1 25
8.3%
14.9%
Q4 24
1.6%
16.9%
Q3 24
4.3%
15.2%
Q2 24
5.8%
13.7%
Q1 24
9.0%
13.5%
Net Margin
SEM
SEM
ZBRA
ZBRA
Q4 25
1.4%
4.7%
Q3 25
2.1%
7.7%
Q2 25
3.0%
8.7%
Q1 25
4.2%
10.4%
Q4 24
-1.2%
12.2%
Q3 24
4.4%
10.9%
Q2 24
6.1%
9.3%
Q1 24
7.3%
9.8%
EPS (diluted)
SEM
SEM
ZBRA
ZBRA
Q4 25
$0.17
$1.40
Q3 25
$0.23
$1.97
Q2 25
$0.32
$2.19
Q1 25
$0.44
$2.62
Q4 24
$-0.12
$3.14
Q3 24
$0.43
$2.64
Q2 24
$0.60
$2.17
Q1 24
$0.75
$2.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SEM
SEM
ZBRA
ZBRA
Cash + ST InvestmentsLiquidity on hand
$26.5M
$125.0M
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$1.7B
$3.6B
Total Assets
$5.9B
$8.5B
Debt / EquityLower = less leverage
1.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SEM
SEM
ZBRA
ZBRA
Q4 25
$26.5M
$125.0M
Q3 25
$60.1M
$1.1B
Q2 25
$52.3M
$872.0M
Q1 25
$53.2M
$879.0M
Q4 24
$59.7M
$901.0M
Q3 24
$191.5M
$676.0M
Q2 24
$111.2M
$411.0M
Q1 24
$92.6M
$127.0M
Total Debt
SEM
SEM
ZBRA
ZBRA
Q4 25
$1.8B
Q3 25
$1.7B
$2.2B
Q2 25
$1.8B
$2.2B
Q1 25
$1.8B
$2.2B
Q4 24
$1.7B
Q3 24
$3.1B
$2.2B
Q2 24
$3.6B
$2.2B
Q1 24
$3.8B
$2.1B
Stockholders' Equity
SEM
SEM
ZBRA
ZBRA
Q4 25
$1.7B
$3.6B
Q3 25
$1.7B
$3.7B
Q2 25
$1.7B
$3.6B
Q1 25
$1.7B
$3.6B
Q4 24
$1.7B
$3.6B
Q3 24
$1.9B
$3.4B
Q2 24
$1.4B
$3.3B
Q1 24
$1.4B
$3.2B
Total Assets
SEM
SEM
ZBRA
ZBRA
Q4 25
$5.9B
$8.5B
Q3 25
$5.7B
$8.1B
Q2 25
$5.7B
$7.9B
Q1 25
$5.7B
$7.9B
Q4 24
$5.6B
$8.0B
Q3 24
$8.0B
$7.7B
Q2 24
$7.9B
$7.5B
Q1 24
$7.9B
$7.3B
Debt / Equity
SEM
SEM
ZBRA
ZBRA
Q4 25
1.06×
Q3 25
1.03×
0.58×
Q2 25
1.10×
0.60×
Q1 25
1.03×
0.60×
Q4 24
1.01×
Q3 24
1.62×
0.64×
Q2 24
2.54×
0.66×
Q1 24
2.75×
0.66×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SEM
SEM
ZBRA
ZBRA
Operating Cash FlowLast quarter
$64.3M
$357.0M
Free Cash FlowOCF − Capex
$5.2M
$327.0M
FCF MarginFCF / Revenue
0.4%
22.2%
Capex IntensityCapex / Revenue
4.2%
2.0%
Cash ConversionOCF / Net Profit
3.19×
5.10×
TTM Free Cash FlowTrailing 4 quarters
$117.2M
$831.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SEM
SEM
ZBRA
ZBRA
Q4 25
$64.3M
$357.0M
Q3 25
$175.3M
$235.0M
Q2 25
$110.3M
$147.0M
Q1 25
$-3.5M
$178.0M
Q4 24
$125.4M
$306.0M
Q3 24
$181.0M
$294.0M
Q2 24
$278.2M
$288.0M
Q1 24
$-66.7M
$125.0M
Free Cash Flow
SEM
SEM
ZBRA
ZBRA
Q4 25
$5.2M
$327.0M
Q3 25
$122.2M
$216.0M
Q2 25
$45.6M
$130.0M
Q1 25
$-55.8M
$158.0M
Q4 24
$62.0M
$288.0M
Q3 24
$130.3M
$277.0M
Q2 24
$222.6M
$278.0M
Q1 24
$-119.2M
$111.0M
FCF Margin
SEM
SEM
ZBRA
ZBRA
Q4 25
0.4%
22.2%
Q3 25
9.0%
16.4%
Q2 25
3.4%
10.1%
Q1 25
-4.1%
12.1%
Q4 24
4.7%
21.6%
Q3 24
10.2%
22.1%
Q2 24
17.4%
22.8%
Q1 24
-9.0%
9.4%
Capex Intensity
SEM
SEM
ZBRA
ZBRA
Q4 25
4.2%
2.0%
Q3 25
3.9%
1.4%
Q2 25
4.8%
1.3%
Q1 25
3.9%
1.5%
Q4 24
4.8%
1.3%
Q3 24
4.0%
1.4%
Q2 24
4.3%
0.8%
Q1 24
4.0%
1.2%
Cash Conversion
SEM
SEM
ZBRA
ZBRA
Q4 25
3.19×
5.10×
Q3 25
6.09×
2.33×
Q2 25
2.72×
1.31×
Q1 25
-0.06×
1.31×
Q4 24
1.88×
Q3 24
3.25×
2.15×
Q2 24
3.59×
2.55×
Q1 24
-0.69×
1.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SEM
SEM

Critical Illness Recovery Hospitals$629.7M45%
Health Care Patient Service Non Medicare$428.6M31%
Rehabilitation Hospitals$339.2M24%

ZBRA
ZBRA

Tangible Products$1.2B83%
Service And Software$255.0M17%

Related Comparisons